



## Clinical trial results:

### A Phase 2 Study of Once-Daily LY3502970 Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities

#### Summary

EudraCT number	2021-002805-88
Trial protocol	HU
Global end of trial date	22 November 2022

#### Results information

Result version number	v1 (current)
This version publication date	08 September 2023
First version publication date	08 September 2023

#### Trial information

##### Trial identification

Sponsor protocol code	J2A-MC-GZGI
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05051579
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 18210

Notes:

#### Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 8772854559,

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 November 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	22 November 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	29 September 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 48
Country: Number of subjects enrolled	Hungary: 31
Country: Number of subjects enrolled	United States: 193
Worldwide total number of subjects	272
EEA total number of subjects	31

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	230
From 65 to 84 years	42

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

For maintenance doses of LY3502970: 12, 24, 36, and 45 milligram (mg), the initial dose will be 2 or 3 mg followed by additional escalation steps as appropriate. The dose-escalation varied by dose group where the target maintenance dose was achieved between Weeks 5 and 16.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	12 mg LY3502970

Arm description:

Participants received maintenance dose 12 mg with dose escalation starting from 3 mg, 6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.

Arm type	Experimental
Investigational medicinal product name	12 mg LY3502970
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Participants received maintenance dose 12 mg with dose escalation starting from 3 mg, 6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.

<b>Arm title</b>	24 mg LY3502970
------------------	-----------------

Arm description:

Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.

Arm type	Experimental
Investigational medicinal product name	24 mg LY3502970
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.

<b>Arm title</b>	36 mg-1 LY3502970
------------------	-------------------

Arm description:

Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	36 mg LY3502970
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.	
<b>Arm title</b>	36 mg-2 LY3502970
Arm description:	
Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.	
Arm type	Experimental
Investigational medicinal product name	36 mg LY3502970
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.	
<b>Arm title</b>	45 mg-1 LY3502970
Arm description:	
Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.	
Arm type	Experimental
Investigational medicinal product name	45 mg LY3502970
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.	
<b>Arm title</b>	45 mg-2 LY3502970
Arm description:	
Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.	
Arm type	Experimental
Investigational medicinal product name	45 mg LY3502970
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.	
<b>Arm title</b>	Placebo
Arm description:	
Participants received placebo administered orally once daily until 36 weeks.	
Arm type	Placebo

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Participants received placebo administered orally once daily until 36 weeks.

<b>Number of subjects in period 1</b>	12 mg LY3502970	24 mg LY3502970	36 mg-1 LY3502970
Started	50	53	29
Completed	44	46	27
Not completed	6	7	2
Consent withdrawn by subject	3	5	2
Patient was Initially Long Term Follow-up But Cont	-	-	-
Adverse event, non-fatal	2	1	-
Sponsor Decision	-	-	-
Subject Unable to Visit Due to Working Out of Town	-	-	-
Lost to follow-up	1	-	-
Inadvertent Enrollment	-	-	-
Subject Could not Tolerate Investigational Product	-	1	-

<b>Number of subjects in period 1</b>	36 mg-2 LY3502970	45 mg-1 LY3502970	45 mg-2 LY3502970
Started	29	31	30
Completed	24	23	28
Not completed	5	8	2
Consent withdrawn by subject	1	4	-
Patient was Initially Long Term Follow-up But Cont	-	1	-
Adverse event, non-fatal	4	1	2
Sponsor Decision	-	1	-
Subject Unable to Visit Due to Working Out of Town	-	-	-
Lost to follow-up	-	1	-
Inadvertent Enrollment	-	-	-
Subject Could not Tolerate Investigational Product	-	-	-

<b>Number of subjects in period 1</b>	Placebo
Started	50
Completed	43
Not completed	7
Consent withdrawn by subject	4

Patient was Initially Long Term Follow-up But Cont	-
Adverse event, non-fatal	-
Sponsor Decision	-
Subject Unable to Visit Due to Working Out of Town	1
Lost to follow-up	1
Inadvertent Enrollment	1
Subject Could not Tolerate Investigational Product	-

## Baseline characteristics

### Reporting groups

Reporting group title	12 mg LY3502970
Reporting group description:	
Participants received maintenance dose 12 mg with dose escalation starting from 3 mg, 6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.	
Reporting group title	24 mg LY3502970
Reporting group description:	
Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.	
Reporting group title	36 mg-1 LY3502970
Reporting group description:	
Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.	
Reporting group title	36 mg-2 LY3502970
Reporting group description:	
Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.	
Reporting group title	45 mg-1 LY3502970
Reporting group description:	
Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.	
Reporting group title	45 mg-2 LY3502970
Reporting group description:	
Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.	
Reporting group title	Placebo
Reporting group description:	
Participants received placebo administered orally once daily until 36 weeks.	

Reporting group values	12 mg LY3502970	24 mg LY3502970	36 mg-1 LY3502970
Number of subjects	50	53	29
Age categorical			
Units: Subjects			

Age continuous			
All randomized participants.			
Units: years			
arithmetic mean	49.80	57.00	56.30
standard deviation	± 10.51	± 9.09	± 11.83
Gender categorical			
All randomized participants.			
Units: Subjects			
Female	31	30	18
Male	19	23	11
Ethnicity (NIH/OMB)			
All randomized participants.			
Units: Subjects			
Hispanic or Latino	11	6	4
Not Hispanic or Latino	38	46	23



Unknown or Not Reported	1	1	2
Race (NIH/OMB)			
All randomized participants.			
Units: Subjects			
American Indian or Alaska Native	0	1	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	3	6	4
White	47	46	25
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Region of Enrollment			
All randomized participants.			
Units: Subjects			
Canada	9	11	5
Hungary	6	5	3
United States	35	37	21
Baseline Body Weight			
All randomized participants.			
Units: Kilograms (kg)			
arithmetic mean	107.49	112.05	107.78
standard deviation	± 25.34	± 30.18	± 22.45

<b>Reporting group values</b>	36 mg-2 LY3502970	45 mg-1 LY3502970	45 mg-2 LY3502970
Number of subjects	29	31	30
Age categorical			
Units: Subjects			

Age continuous			
All randomized participants.			
Units: years			
arithmetic mean	55.40	56.50	50.90
standard deviation	± 10.93	± 10.74	± 12.58
Gender categorical			
All randomized participants.			
Units: Subjects			
Female	18	19	16
Male	11	12	14
Ethnicity (NIH/OMB)			
All randomized participants.			
Units: Subjects			
Hispanic or Latino	2	4	7
Not Hispanic or Latino	26	25	22
Unknown or Not Reported	1	2	1
Race (NIH/OMB)			
All randomized participants.			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0

Black or African American	4	1	0
White	25	29	30
More than one race	0	0	0
Unknown or Not Reported	0	1	0
Region of Enrollment			
All randomized participants.			
Units: Subjects			
Canada	3	9	5
Hungary	6	3	3
United States	20	19	22
Baseline Body Weight			
All randomized participants.			
Units: Kilograms (kg)			
arithmetic mean	108.84	105.23	110.85
standard deviation	± 28.52	± 20.40	± 28.11

<b>Reporting group values</b>	Placebo	Total	
Number of subjects	50	272	
Age categorical			
Units: Subjects			

Age continuous			
All randomized participants.			
Units: years			
arithmetic mean	54.00		
standard deviation	± 8.82	-	
Gender categorical			
All randomized participants.			
Units: Subjects			
Female	29	161	
Male	21	111	
Ethnicity (NIH/OMB)			
All randomized participants.			
Units: Subjects			
Hispanic or Latino	5	39	
Not Hispanic or Latino	43	223	
Unknown or Not Reported	2	10	
Race (NIH/OMB)			
All randomized participants.			
Units: Subjects			
American Indian or Alaska Native	0	1	
Asian	2	2	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	1	19	
White	45	247	
More than one race	2	2	
Unknown or Not Reported	0	1	
Region of Enrollment			
All randomized participants.			
Units: Subjects			

Canada	6	48	
Hungary	5	31	
United States	39	193	
Baseline Body Weight			
All randomized participants.			
Units: Kilograms (kg)			
arithmetic mean	107.57		
standard deviation	± 25.24	-	

## End points

### End points reporting groups

Reporting group title	12 mg LY3502970
Reporting group description: Participants received maintenance dose 12 mg with dose escalation starting from 3 mg, 6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.	
Reporting group title	24 mg LY3502970
Reporting group description: Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.	
Reporting group title	36 mg-1 LY3502970
Reporting group description: Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.	
Reporting group title	36 mg-2 LY3502970
Reporting group description: Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.	
Reporting group title	45 mg-1 LY3502970
Reporting group description: Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.	
Reporting group title	45 mg-2 LY3502970
Reporting group description: Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.	
Reporting group title	Placebo
Reporting group description: Participants received placebo administered orally once daily until 36 weeks.	
Subject analysis set title	36 mg LY3502970
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks.	
Subject analysis set title	45 mg LY3502970
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks.	
Subject analysis set title	Placebo
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: Participants received placebo administered orally once daily until 36 weeks.	

### Primary: Percent Change from Baseline in Body Weight in LY3502970 and Placebo

End point title	Percent Change from Baseline in Body Weight in LY3502970 and Placebo <sup>[1]</sup>
End point description: Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment*Time (Type III sum of squares)	

as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured. Analysis population of description (APD) included all randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body weight value.

End point type	Primary
End point timeframe:	
Baseline, Week 26	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Descriptive statistics was added in baseline period reporting arms, subject analysis set with evaluable endpoint data.

End point values	12 mg LY3502970	24 mg LY3502970	36 mg LY3502970	45 mg LY3502970
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	44	51	56	57
Units: Percent change				
least squares mean (standard error)	-8.6 (± 0.85)	-11.2 (± 0.82)	-12.3 (± 0.77)	-12.6 (± 0.75)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: Percent change				
least squares mean (standard error)	-2.0 (± 0.81)			

## Statistical analyses

Statistical analysis title	Percent Change from Baseline in Body Weight
Comparison groups	12 mg LY3502970 v Placebo
Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-6.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.9
upper limit	-4.2

Statistical analysis title	Percent Change from Baseline in Body Weight
Comparison groups	24 mg LY3502970 v Placebo

Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-9.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.5
upper limit	-6.9

<b>Statistical analysis title</b>	Percent Change from Baseline in Body Weight
Comparison groups	36 mg LY3502970 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-10.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.4
upper limit	-8

<b>Statistical analysis title</b>	Percent Change from Baseline in Body Weight
Comparison groups	45 mg LY3502970 v Placebo
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-10.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.7
upper limit	-8.4

## Secondary: Percent Change from Baseline in Body Weight in LY3502970 and Placebo

End point title	Percent Change from Baseline in Body Weight in LY3502970 and Placebo <sup>[2]</sup>
End point description: LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured. APD included all randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body weight value.	
End point type	Secondary
End point timeframe: Baseline, Week 36	

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Descriptive statistics was added in baseline period reporting arms, subject analysis set with evaluable endpoint data.

End point values	12 mg LY3502970	24 mg LY3502970	36 mg LY3502970	45 mg LY3502970
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	44	51	56	57
Units: Percent change				
least squares mean (standard error)	-9.4 (± 1.05)	-12.5 (± 1.01)	-13.5 (± 0.95)	-14.7 (± 0.94)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: Percent change				
least squares mean (standard error)	-2.3 (± 1.00)			

## Statistical analyses

Statistical analysis title	Percent Change from Baseline in Body Weight
Comparison groups	12 mg LY3502970 v Placebo
Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-7.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.9
upper limit	-4.2

<b>Statistical analysis title</b>	Percent Change from Baseline in Body Weight
Comparison groups	24 mg LY3502970 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-10.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.9
upper limit	-7.3

<b>Statistical analysis title</b>	Percent Change from Baseline in Body Weight
Comparison groups	36 mg LY3502970 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-11.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.8
upper limit	-8.4

<b>Statistical analysis title</b>	Percent Change from Baseline in Body Weight
Comparison groups	45 mg LY3502970 v Placebo
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-12.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15
upper limit	-9.6



## Secondary: Change from Baseline in Body Weight in LY3502970 and Placebo

End point title	Change from Baseline in Body Weight in LY3502970 and Placebo <sup>[3]</sup>
-----------------	---

End point description:

LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured. APD included all randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body weight value.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 26

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Descriptive statistics was added in baseline period reporting arms, subject analysis set with evaluable endpoint data.

End point values	12 mg LY3502970	24 mg LY3502970	36 mg LY3502970	45 mg LY3502970
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	44	51	56	57
Units: kg				
least squares mean (standard error)	-9.0 (± 0.90)	-12.3 (± 0.86)	-12.9 (± 0.82)	-13.3 (± 0.79)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: kg				
least squares mean (standard error)	-2.1 (± 0.86)			

## Statistical analyses

Statistical analysis title	Change from Baseline in Body Weight in LY3502970
Comparison groups	12 mg LY3502970 v Placebo
Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-6.9

Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.3
upper limit	-4.4

<b>Statistical analysis title</b>	Change from Baseline in Body Weight in LY3502970
Comparison groups	24 mg LY3502970 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-10.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.5
upper limit	-7.8

<b>Statistical analysis title</b>	Change from Baseline in Body Weight in LY3502970
Comparison groups	36 mg LY3502970 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-10.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.1
upper limit	-8.5

<b>Statistical analysis title</b>	Change from Baseline in Body Weight in LY3502970
Comparison groups	45 mg LY3502970 v Placebo

Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-11.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.5
upper limit	-8.9

## Secondary: Change From Baseline in Body Weight in LY3502970 and Placebo

End point title	Change From Baseline in Body Weight in LY3502970 and Placebo <sup>[4]</sup>
-----------------	---

End point description:

LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured. APD included all randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body weight value.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 36

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Descriptive statistics was added in baseline period reporting arms, subject analysis set with evaluable endpoint data.

End point values	12 mg LY3502970	24 mg LY3502970	36 mg LY3502970	45 mg LY3502970
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	44	51	56	57
Units: kg				
least squares mean (standard error)	-9.8 (± 1.10)	-13.6 (± 1.06)	-14.2 (± 1.00)	-15.4 (± 0.98)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: kg				
least squares mean (standard error)	-2.4 (± 1.05)			

## Statistical analyses

<b>Statistical analysis title</b>	Change From Baseline in Body Weight
Comparison groups	12 mg LY3502970 v Placebo
Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-7.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.4
upper limit	-4.3

<b>Statistical analysis title</b>	Change From Baseline in Body Weight
Comparison groups	24 mg LY3502970 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-11.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.2
upper limit	-8.3

<b>Statistical analysis title</b>	Change From Baseline in Body Weight
Comparison groups	36 mg LY3502970 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-11.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.7
upper limit	-9

<b>Statistical analysis title</b>	Change From Baseline in Body Weight
Comparison groups	45 mg LY3502970 v Placebo
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-13
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.8
upper limit	-10.2

## Secondary: Change from Baseline in Waist Circumference in LY3502970 and Placebo

End point title	Change from Baseline in Waist Circumference in LY3502970 and Placebo <sup>[5]</sup>
-----------------	---

End point description:

LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured. APD included all randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body waist circumference value.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 26

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Descriptive statistics was added in baseline period reporting arms, subject analysis set with evaluable endpoint data.

<b>End point values</b>	12 mg LY3502970	24 mg LY3502970	36 mg LY3502970	45 mg LY3502970
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	43	49	52	57
Units: centimeter (cm)				
least squares mean (standard error)	-8.0 (± 1.03)	-8.8 (± 1.00)	-10.1 (± 0.94)	-12.2 (± 0.93)

<b>End point values</b>	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: centimeter (cm)				
least squares mean (standard error)	-3.6 (± 0.99)			

### Statistical analyses

<b>Statistical analysis title</b>	Change from Baseline in Waist Circumference
Comparison groups	12 mg LY3502970 v Placebo
Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.002
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-4.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.2
upper limit	-1.6

<b>Statistical analysis title</b>	Change from Baseline in Waist Circumference
Comparison groups	24 mg LY3502970 v Placebo
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-5.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8
upper limit	-2.4

<b>Statistical analysis title</b>	Change from Baseline in Waist Circumference
Comparison groups	36 mg LY3502970 v Placebo

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-6.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.2
upper limit	-3.8

<b>Statistical analysis title</b>	Change from Baseline in Waist Circumference
Comparison groups	45 mg LY3502970 v Placebo
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-8.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.3
upper limit	-6

## Secondary: Change From Baseline in Waist Circumference in LY3502970 and Placebo

End point title	Change From Baseline in Waist Circumference in LY3502970 and Placebo <sup>[6]</sup>
-----------------	---

### End point description:

LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured. APD included all randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body waist circumference value.

End point type	Secondary
----------------	-----------

### End point timeframe:

Baseline, Week 36

### Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Descriptive statistics was added in baseline period reporting arms, subject analysis set with evaluable endpoint data.

End point values	12 mg LY3502970	24 mg LY3502970	36 mg LY3502970	45 mg LY3502970
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	43	49	52	57
Units: cm				
least squares mean (standard error)	-9.6 (± 1.18)	-11.2 (± 1.15)	-10.6 (± 1.06)	-13.6 (± 1.07)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: cm				
least squares mean (standard error)	-4.0 (± 1.12)			

## Statistical analyses

Statistical analysis title	Change From Baseline in Waist Circumference
Comparison groups	12 mg LY3502970 v Placebo
Number of subjects included in analysis	91
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-5.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.8
upper limit	-2.4

Statistical analysis title	Change From Baseline in Waist Circumference
Comparison groups	24 mg LY3502970 v Placebo
Number of subjects included in analysis	97
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-7.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.3
upper limit	-4



<b>Statistical analysis title</b>	Change From Baseline in Waist Circumference
Comparison groups	36 mg LY3502970 v Placebo
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-6.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.7
upper limit	-3.6

<b>Statistical analysis title</b>	Change From Baseline in Waist Circumference
Comparison groups	45 mg LY3502970 v Placebo
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-9.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.7
upper limit	-6.6

## Secondary: Change from Baseline in BMI in LY3502970 and Placebo

End point title	Change from Baseline in BMI in LY3502970 and Placebo <sup>[7]</sup>
End point description:	
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured. APD included all randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline BMI value.	
End point type	Secondary
End point timeframe:	
Baseline, Week 26	

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Descriptive statistics was added in baseline period reporting arms, subject analysis set with evaluable endpoint data.

End point values	12 mg LY3502970	24 mg LY3502970	36 mg LY3502970	45 mg LY3502970
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	44	51	56	57
Units: kilograms per meter square (kg/m <sup>2</sup> )				
least squares mean (standard error)	-3.2 (± 0.21)	-4.2 (± 0.30)	-4.6 (± 0.28)	-4.7 (± 0.27)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: kilograms per meter square (kg/m <sup>2</sup> )				
least squares mean (standard error)	-0.8 (± 0.29)			

## Statistical analyses

Statistical analysis title	Change from Baseline in BMI
Comparison groups	12 mg LY3502970 v Placebo
Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-2.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.2
upper limit	-1.6

Statistical analysis title	Change from Baseline in BMI
Comparison groups	24 mg LY3502970 v Placebo

Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.3
upper limit	-2.6

<b>Statistical analysis title</b>	Change from Baseline in BMI
Comparison groups	36 mg LY3502970 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.6
upper limit	3

<b>Statistical analysis title</b>	Change from Baseline in BMI
Comparison groups	45 mg LY3502970 v Placebo
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-3.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.7
upper limit	-3.1

---

## Secondary: Change From Baseline in BMI in LY3502970 and Placebo

End point title	Change From Baseline in BMI in LY3502970 and Placebo <sup>[8]</sup>
End point description:	
LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured. APD included all randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline BMI value.	
End point type	Secondary
End point timeframe:	
Baseline, Week 36	

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: Descriptive statistics was added in baseline period reporting arms, subject analysis set with evaluable endpoint data.

End point values	12 mg LY3502970	24 mg LY3502970	36 mg LY3502970	45 mg LY3502970
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	44	51	56	57
Units: kg/m <sup>2</sup>				
least squares mean (standard error)	-3.4 (± 0.38)	-4.7 (± 0.36)	-5.0 (± 0.34)	-5.5 (± 0.34)

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: kg/m <sup>2</sup>				
least squares mean (standard error)	-0.9 (± 0.36)			

## Statistical analyses

Statistical analysis title	Change From Baseline in BMI
Comparison groups	12 mg LY3502970 v Placebo
Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.6
upper limit	-1.5

<b>Statistical analysis title</b>	Change From Baseline in BMI
Comparison groups	24 mg LY3502970 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.8
upper limit	-2.8

<b>Statistical analysis title</b>	Change From Baseline in BMI
Comparison groups	36 mg LY3502970 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-4.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.2
upper limit	-3.2

<b>Statistical analysis title</b>	Change From Baseline in BMI
Comparison groups	45 mg LY3502970 v Placebo
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LS Mean difference (Final Values)
Point estimate	-4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.6
upper limit	-3.6

## Secondary: Percentage of Participants with $\geq 5\%$ Body Weight Loss

End point title	Percentage of Participants with $\geq 5\%$ Body Weight Loss <sup>[9]</sup>
-----------------	--

End point description:

Percentage of participants with  $\geq 5\%$  body weight loss was reported. APD included all randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value for  $\geq 5\%$  body weight reduction.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 26

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Descriptive statistics was added in baseline period reporting arms, subject analysis set with evaluable endpoint data.

End point values	12 mg LY3502970	24 mg LY3502970	36 mg LY3502970	45 mg LY3502970
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	44	51	56	57
Units: percentage of participants				
number (not applicable)	74.39	88.84	89.46	87.26

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: percentage of participants				
number (not applicable)	22.88			

## Statistical analyses

Statistical analysis title	Percentage of Participants with $\geq 5\%$ Body Weight
Comparison groups	12 mg LY3502970 v Placebo
Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	9.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.61
upper limit	27.44

<b>Statistical analysis title</b>	Percentage of Participants with $\geq 5\%$ Body Weight
Comparison groups	24 mg LY3502970 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	other
P-value	$< 0.001$
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	27.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.15
upper limit	96.01

<b>Statistical analysis title</b>	Percentage of Participants with $\geq 5\%$ Body Weight
Comparison groups	36 mg LY3502970 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other
P-value	$< 0.001$
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	27.36
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.71
upper limit	85.91

<b>Statistical analysis title</b>	Percentage of Participants with $\geq 5\%$ Body Weight
Comparison groups	45 mg LY3502970 v Placebo
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	other
P-value	$< 0.001$
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	23.59

Confidence interval	
level	95 %
sides	2-sided
lower limit	7.65
upper limit	72.77

## Secondary: Percentage of Participants with $\geq 10\%$ Body Weight Loss

End point title	Percentage of Participants with $\geq 10\%$ Body Weight Loss <sup>[10]</sup>
-----------------	--

End point description:

Percentage of participants with  $\geq 10\%$  body weight loss was reported. APD included all randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value for  $\geq 10\%$  body weight reduction.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 26

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Descriptive statistics was added in baseline period reporting arms, subject analysis set with evaluable endpoint data.

End point values	12 mg LY3502970	24 mg LY3502970	36 mg LY3502970	45 mg LY3502970
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	44	51	56	57
Units: percentage of participants				
number (not applicable)	39.39	56.61	71.30	69.86

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: percentage of participants				
number (not applicable)	2.25			

## Statistical analyses

Statistical analysis title	Percentage of Participants with $\geq 10\%$ Body Weight
Comparison groups	12 mg LY3502970 v Placebo



Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	19.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.47
upper limit	114.4

<b>Statistical analysis title</b>	Percentage of Participants with $\geq 10\%$ Body Weight
Comparison groups	24 mg LY3502970 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	39.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.95
upper limit	224.83

<b>Statistical analysis title</b>	Percentage of Participants with $\geq 10\%$ Body Weight
Comparison groups	36 mg LY3502970 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	74.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	13.16
upper limit	427.18

<b>Statistical analysis title</b>	Percentage of Participants with $\geq 10\%$ Body Weight
-----------------------------------	---

Comparison groups	45 mg LY3502970 v Placebo
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	72.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.62
upper limit	413.21

### Secondary: Percentage of Participants with $\geq 5\%$ Body Weight Loss

End point title	Percentage of Participants with $\geq 5\%$ Body Weight Loss <sup>[11]</sup>
-----------------	---

End point description:

Percentage of participants with  $\geq 5\%$  body weight loss was reported. APD included all randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value for  $\geq 5\%$  body weight reduction.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 36

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Descriptive statistics was added in baseline period reporting arms, subject analysis set with evaluable endpoint data.

End point values	12 mg LY3502970	24 mg LY3502970	36 mg LY3502970	45 mg LY3502970
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	44	51	56	57
Units: percentage of participants				
number (not applicable)	72.00	89.47	92.05	90.44

End point values	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: percentage of participants				
number (not applicable)	24.02			

### Statistical analyses

<b>Statistical analysis title</b>	Percentage of Participants with $\geq 5\%$ Body Weight
Comparison groups	12 mg LY3502970 v Placebo
Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	other
P-value	$< 0.001$
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	7.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.9
upper limit	20.92

<b>Statistical analysis title</b>	Percentage of Participants with $\geq 5\%$ Body Weight
Comparison groups	24 mg LY3502970 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	other
P-value	$< 0.001$
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	25.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.49
upper limit	83.91

<b>Statistical analysis title</b>	Percentage of Participants with $\geq 5\%$ Body Weight
Comparison groups	36 mg LY3502970 v Placebo
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other
P-value	$< 0.001$
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	34.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.17
upper limit	147.86

<b>Statistical analysis title</b>	Percentage of Participants with $\geq 5\%$ Body Weight
Comparison groups	45 mg LY3502970 v Placebo
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	other
P-value	$< 0.001$
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	28.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.15
upper limit	96.29

## Secondary: Percentage of Participants with $\geq 10\%$ Body Weight Loss

End point title	Percentage of Participants with $\geq 10\%$ Body Weight Loss <sup>[12]</sup>
-----------------	--

End point description:

Percentage of participants with  $\geq 10\%$  body weight loss was reported. APD included all randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value for  $\geq 10\%$  body weight reduction.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 36

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Descriptive statistics was added in baseline period reporting arms, subject analysis set with evaluable endpoint data.

<b>End point values</b>	12 mg LY3502970	24 mg LY3502970	36 mg LY3502970	45 mg LY3502970
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	44	51	56	57
Units: percentage of participants				
number (not applicable)	46.50	61.88	74.75	69.07

<b>End point values</b>	Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	48			
Units: percentage of participants				
number (not applicable)	8.85			

### Statistical analyses

<b>Statistical analysis title</b>	Percentage of Participants with $\geq 10\%$ Body Weight
Comparison groups	12 mg LY3502970 v Placebo
Number of subjects included in analysis	92
Analysis specification	Pre-specified
Analysis type	other
P-value	$< 0.001$
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	8.27
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.59
upper limit	26.45

<b>Statistical analysis title</b>	Percentage of Participants with $\geq 10\%$ Body Weight
Comparison groups	24 mg LY3502970 v Placebo
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	other
P-value	$< 0.001$
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	15.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.83
upper limit	50.68

<b>Statistical analysis title</b>	Percentage of Participants with $\geq 10\%$ Body Weight
Comparison groups	36 mg LY3502970 v Placebo

Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	27.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.39
upper limit	88.38

<b>Statistical analysis title</b>	Percentage of Participants with $\geq 10\%$ Body Weight
Comparison groups	45 mg LY3502970 v Placebo
Number of subjects included in analysis	105
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	20.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.59
upper limit	66.17

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline through Week 38 (36 weeks follow up with 2 weeks safety follow up)

Adverse event reporting additional description:

All randomized participants who received at least one dose of study drug regardless of adherence to study drug. Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.1
--------------------	------

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received placebo administered orally once daily until 36 weeks.

Reporting group title	12 mg LY3502970
-----------------------	-----------------

Reporting group description:

Participants received maintenance dose 12 mg with dose escalation starting from 3 mg, 6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.

Reporting group title	24 mg LY3502970
-----------------------	-----------------

Reporting group description:

Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.

Reporting group title	45 mg-2 LY3502970
-----------------------	-------------------

Reporting group description:

Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.

Reporting group title	36 mg-2 LY3502970
-----------------------	-------------------

Reporting group description:

Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

Reporting group title	45 mg-1 LY3502970
-----------------------	-------------------

Reporting group description:

Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.

Reporting group title	36 mg-1 LY3502970
-----------------------	-------------------

Reporting group description:

Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

Serious adverse events	Placebo	12 mg LY3502970	24 mg LY3502970
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	2 / 53 (3.77%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Neoplasms benign, malignant and unspecified (incl cysts and polyps) hepatic cancer metastatic alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 50 (0.00%) 0 / 0 0 / 0	0 / 50 (0.00%) 0 / 0 0 / 0	0 / 53 (0.00%) 0 / 0 0 / 0
Cardiac disorders coronary artery disease alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 50 (0.00%) 0 / 0 0 / 0	0 / 50 (0.00%) 0 / 0 0 / 0	0 / 53 (0.00%) 0 / 0 0 / 0
Eye disorders retinal vein thrombosis alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 50 (0.00%) 0 / 0 0 / 0	0 / 50 (0.00%) 0 / 0 0 / 0	0 / 53 (0.00%) 0 / 0 0 / 0
vitreoretinal traction syndrome alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 50 (0.00%) 0 / 0 0 / 0	0 / 50 (0.00%) 0 / 0 0 / 0	0 / 53 (0.00%) 0 / 0 0 / 0
Gastrointestinal disorders diverticulum intestinal alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 50 (0.00%) 0 / 0 0 / 0	0 / 50 (0.00%) 0 / 0 0 / 0	0 / 53 (0.00%) 0 / 0 0 / 0
gastrointestinal polyp haemorrhage alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 50 (0.00%) 0 / 0 0 / 0	0 / 50 (0.00%) 0 / 0 0 / 0	1 / 53 (1.89%) 1 / 1 0 / 0



Hepatobiliary disorders			
cholecystitis acute			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	1 / 53 (1.89%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
hypercalcaemia			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Serious adverse events</b>	<b>45 mg-2 LY3502970</b>	<b>36 mg-2 LY3502970</b>	<b>45 mg-1 LY3502970</b>
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 30 (0.00%)	3 / 29 (10.34%)	2 / 31 (6.45%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
hepatic cancer metastatic			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 30 (0.00%)	1 / 29 (3.45%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
coronary artery disease			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	1 / 31 (3.23%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
retinal vein thrombosis			
alternative dictionary used: MedDRA 25.1			

subjects affected / exposed	0 / 30 (0.00%)	1 / 29 (3.45%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
vitreoretinal traction syndrome alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	1 / 31 (3.23%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders diverticulum intestinal alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 30 (0.00%)	1 / 29 (3.45%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gastrointestinal polyp haemorrhage alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders cholecystitis acute alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 30 (0.00%)	0 / 29 (0.00%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders hypercalcaemia alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 30 (0.00%)	1 / 29 (3.45%)	0 / 31 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Serious adverse events</b>	36 mg-1 LY3502970		
Total subjects affected by serious adverse events			

subjects affected / exposed	0 / 29 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
hepatic cancer metastatic			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 29 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
coronary artery disease			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 29 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
retinal vein thrombosis			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 29 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
vitreoretinal traction syndrome			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 29 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
diverticulum intestinal			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 29 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
gastrointestinal polyp haemorrhage			
alternative dictionary used: MedDRA 25.1			

subjects affected / exposed	0 / 29 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
cholecystitis acute			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 29 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
hypercalcaemia			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 29 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo	12 mg LY3502970	24 mg LY3502970
Total subjects affected by non-serious adverse events			
subjects affected / exposed	27 / 50 (54.00%)	35 / 50 (70.00%)	46 / 53 (86.79%)
Vascular disorders			
hypotension			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	0 / 53 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
atrioventricular block first degree			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	0 / 53 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
dizziness			
alternative dictionary used: MedDRA 25.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>headache</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 50 (2.00%)</p> <p>1</p> <p>5 / 50 (10.00%)</p> <p>5</p> <p>5 / 50 (10.00%)</p> <p>7</p>	<p>5 / 50 (10.00%)</p> <p>5</p> <p>4 / 50 (8.00%)</p> <p>4</p>	<p>2 / 53 (3.77%)</p> <p>3</p> <p>8 / 53 (15.09%)</p> <p>11</p>
<p>General disorders and administration site conditions</p> <p>chills</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>fatigue</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 50 (0.00%)</p> <p>0</p> <p>1 / 50 (2.00%)</p> <p>1</p>	<p>1 / 50 (2.00%)</p> <p>1</p> <p>2 / 50 (4.00%)</p> <p>2</p>	<p>1 / 53 (1.89%)</p> <p>1</p> <p>7 / 53 (13.21%)</p> <p>8</p>
<p>Gastrointestinal disorders</p> <p>abdominal pain</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>abdominal discomfort</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>abdominal distension</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>abdominal pain upper</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dyspepsia</p> <p>alternative dictionary used: MedDRA 25.1</p>	<p>2 / 50 (4.00%)</p> <p>2</p> <p>1 / 50 (2.00%)</p> <p>1</p> <p>1 / 50 (2.00%)</p> <p>1</p> <p>1 / 50 (2.00%)</p> <p>1</p>	<p>4 / 50 (8.00%)</p> <p>4</p> <p>0 / 50 (0.00%)</p> <p>0</p> <p>1 / 50 (2.00%)</p> <p>1</p> <p>1 / 50 (2.00%)</p> <p>1</p>	<p>4 / 53 (7.55%)</p> <p>5</p> <p>4 / 53 (7.55%)</p> <p>4</p> <p>4 / 53 (7.55%)</p> <p>5</p> <p>3 / 53 (5.66%)</p> <p>3</p>

subjects affected / exposed	3 / 50 (6.00%)	8 / 50 (16.00%)	4 / 53 (7.55%)
occurrences (all)	4	11	4
diarrhoea			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	5 / 50 (10.00%)	12 / 50 (24.00%)	19 / 53 (35.85%)
occurrences (all)	6	23	29
constipation			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	3 / 50 (6.00%)	12 / 50 (24.00%)	17 / 53 (32.08%)
occurrences (all)	3	16	21
gastrooesophageal reflux disease			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	1 / 50 (2.00%)	4 / 50 (8.00%)	5 / 53 (9.43%)
occurrences (all)	1	4	6
flatulence			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	2 / 50 (4.00%)	0 / 50 (0.00%)	3 / 53 (5.66%)
occurrences (all)	2	0	3
eructation			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 50 (0.00%)	9 / 50 (18.00%)	11 / 53 (20.75%)
occurrences (all)	0	15	14
vomiting			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	3 / 50 (6.00%)	13 / 50 (26.00%)	17 / 53 (32.08%)
occurrences (all)	3	23	33
nausea			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	5 / 50 (10.00%)	25 / 50 (50.00%)	31 / 53 (58.49%)
occurrences (all)	6	39	50
Reproductive system and breast disorders			
balanoposthitis			
alternative dictionary used: MedDRA 25.1			

subjects affected / exposed <sup>[1]</sup> occurrences (all)	0 / 21 (0.00%) 0	0 / 19 (0.00%) 0	0 / 23 (0.00%) 0
erectile dysfunction alternative dictionary used: MedDRA 25.1 subjects affected / exposed <sup>[2]</sup> occurrences (all)	0 / 21 (0.00%) 0	1 / 19 (5.26%) 1	0 / 23 (0.00%) 0
postmenopausal haemorrhage alternative dictionary used: MedDRA 25.1 subjects affected / exposed <sup>[3]</sup> occurrences (all)	0 / 29 (0.00%) 0	0 / 31 (0.00%) 0	0 / 30 (0.00%) 0
vulvovaginal pruritus alternative dictionary used: MedDRA 25.1 subjects affected / exposed <sup>[4]</sup> occurrences (all)	0 / 29 (0.00%) 0	0 / 31 (0.00%) 0	0 / 30 (0.00%) 0
Respiratory, thoracic and mediastinal disorders oropharyngeal pain alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 2	0 / 50 (0.00%) 0	0 / 53 (0.00%) 0
Skin and subcutaneous tissue disorders alopecia alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	1 / 50 (2.00%) 1	1 / 53 (1.89%) 1
Renal and urinary disorders dysuria alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 50 (0.00%) 0	0 / 53 (0.00%) 0
Musculoskeletal and connective tissue disorders back pain alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  arthralgia	4 / 50 (8.00%) 4	1 / 50 (2.00%) 1	2 / 53 (3.77%) 2

<p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 50 (2.00%)</p> <p>1</p>	<p>1 / 50 (2.00%)</p> <p>1</p>	<p>5 / 53 (9.43%)</p> <p>5</p>
<p>myalgia</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 50 (2.00%)</p> <p>1</p>	<p>0 / 50 (0.00%)</p> <p>0</p>	<p>1 / 53 (1.89%)</p> <p>1</p>
<p>muscle spasms</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 50 (0.00%)</p> <p>0</p>	<p>0 / 50 (0.00%)</p> <p>0</p>	<p>1 / 53 (1.89%)</p> <p>1</p>
<p>pain in extremity</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 50 (2.00%)</p> <p>1</p>	<p>1 / 50 (2.00%)</p> <p>1</p>	<p>1 / 53 (1.89%)</p> <p>1</p>
<p>Infections and infestations</p> <p>covid-19</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>9 / 50 (18.00%)</p> <p>9</p>	<p>9 / 50 (18.00%)</p> <p>11</p>	<p>9 / 53 (16.98%)</p> <p>9</p>
<p>nasopharyngitis</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 50 (0.00%)</p> <p>0</p>	<p>1 / 50 (2.00%)</p> <p>2</p>	<p>2 / 53 (3.77%)</p> <p>2</p>
<p>urinary tract infection</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 50 (6.00%)</p> <p>3</p>	<p>2 / 50 (4.00%)</p> <p>2</p>	<p>3 / 53 (5.66%)</p> <p>4</p>
<p>upper respiratory tract infection</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 50 (2.00%)</p> <p>1</p>	<p>3 / 50 (6.00%)</p> <p>3</p>	<p>0 / 53 (0.00%)</p> <p>0</p>
<p>sinusitis</p> <p>alternative dictionary used: MedDRA 25.1</p>			



subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	1 / 50 (2.00%) 1	3 / 53 (5.66%) 3
Metabolism and nutrition disorders decreased appetite alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	4 / 50 (8.00%) 4	4 / 53 (7.55%) 5

<b>Non-serious adverse events</b>	45 mg-2 LY3502970	36 mg-2 LY3502970	45 mg-1 LY3502970
Total subjects affected by non-serious adverse events			
subjects affected / exposed	24 / 30 (80.00%)	25 / 29 (86.21%)	26 / 31 (83.87%)
Vascular disorders hypotension alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	3 / 30 (10.00%) 3	0 / 29 (0.00%) 0	1 / 31 (3.23%) 1
Cardiac disorders atrioventricular block first degree alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	3 / 30 (10.00%) 3	0 / 29 (0.00%) 0	0 / 31 (0.00%) 0
Nervous system disorders dizziness alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  headache alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	4 / 30 (13.33%) 4  2 / 30 (6.67%) 3	1 / 29 (3.45%) 1  2 / 29 (6.90%) 2	2 / 31 (6.45%) 2  4 / 31 (12.90%) 6
General disorders and administration site conditions chills alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  fatigue	0 / 30 (0.00%) 0	0 / 29 (0.00%) 0	2 / 31 (6.45%) 2

alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	4 / 30 (13.33%) 6	2 / 29 (6.90%) 2	4 / 31 (12.90%) 5
Gastrointestinal disorders			
abdominal pain alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 3	2 / 29 (6.90%) 2	2 / 31 (6.45%) 2
abdominal discomfort alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 29 (3.45%) 1	4 / 31 (12.90%) 4
abdominal distension alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	1 / 29 (3.45%) 1	1 / 31 (3.23%) 1
abdominal pain upper alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	3 / 30 (10.00%) 3	2 / 29 (6.90%) 2	0 / 31 (0.00%) 0
dyspepsia alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	1 / 29 (3.45%) 1	3 / 31 (9.68%) 3
diarrhoea alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	10 / 30 (33.33%) 16	4 / 29 (13.79%) 5	5 / 31 (16.13%) 5
constipation alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	4 / 30 (13.33%) 5	7 / 29 (24.14%) 10	6 / 31 (19.35%) 8
gastrooesophageal reflux disease alternative dictionary used: MedDRA 25.1			

subjects affected / exposed	2 / 30 (6.67%)	4 / 29 (13.79%)	4 / 31 (12.90%)
occurrences (all)	2	5	6
flatulence			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 30 (0.00%)	1 / 29 (3.45%)	1 / 31 (3.23%)
occurrences (all)	0	1	1
eructation			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	6 / 30 (20.00%)	2 / 29 (6.90%)	2 / 31 (6.45%)
occurrences (all)	9	2	2
vomiting			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	8 / 30 (26.67%)	4 / 29 (13.79%)	9 / 31 (29.03%)
occurrences (all)	15	9	14
nausea			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	11 / 30 (36.67%)	14 / 29 (48.28%)	13 / 31 (41.94%)
occurrences (all)	23	18	28
Reproductive system and breast disorders			
balanoposthitis			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed <sup>[1]</sup>	0 / 14 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
erectile dysfunction			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed <sup>[2]</sup>	0 / 14 (0.00%)	0 / 11 (0.00%)	0 / 12 (0.00%)
occurrences (all)	0	0	0
postmenopausal haemorrhage			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed <sup>[3]</sup>	0 / 16 (0.00%)	1 / 18 (5.56%)	1 / 19 (5.26%)
occurrences (all)	0	1	1
vulvovaginal pruritus			
alternative dictionary used: MedDRA 25.1			

subjects affected / exposed <sup>[4]</sup> occurrences (all)	0 / 16 (0.00%) 0	0 / 18 (0.00%) 0	0 / 19 (0.00%) 0
Respiratory, thoracic and mediastinal disorders oropharyngeal pain alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	2 / 29 (6.90%) 2	0 / 31 (0.00%) 0
Skin and subcutaneous tissue disorders alopecia alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	0 / 29 (0.00%) 0	3 / 31 (9.68%) 3
Renal and urinary disorders dysuria alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 29 (3.45%) 1	1 / 31 (3.23%) 1
Musculoskeletal and connective tissue disorders back pain alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  arthralgia alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  myalgia alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  muscle spasms alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  pain in extremity	1 / 30 (3.33%) 1  1 / 30 (3.33%) 1  0 / 30 (0.00%) 0  2 / 30 (6.67%) 2	1 / 29 (3.45%) 1  1 / 29 (3.45%) 1  0 / 29 (0.00%) 0  0 / 29 (0.00%) 0	1 / 31 (3.23%) 1  1 / 31 (3.23%) 2  0 / 31 (0.00%) 0  1 / 31 (3.23%) 1

alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	2 / 29 (6.90%) 2	0 / 31 (0.00%) 0
Infections and infestations covid-19 alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	5 / 30 (16.67%) 5	7 / 29 (24.14%) 7	5 / 31 (16.13%) 5
nasopharyngitis alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	0 / 29 (0.00%) 0	1 / 31 (3.23%) 1
urinary tract infection alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	3 / 29 (10.34%) 3	1 / 31 (3.23%) 1
upper respiratory tract infection alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	1 / 29 (3.45%) 1	1 / 31 (3.23%) 1
sinusitis alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	0 / 29 (0.00%) 0	0 / 31 (0.00%) 0
Metabolism and nutrition disorders decreased appetite alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	1 / 29 (3.45%) 1	3 / 31 (9.68%) 3

<b>Non-serious adverse events</b>	36 mg-1 LY3502970		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	23 / 29 (79.31%)		
Vascular disorders			
hypotension alternative dictionary used: MedDRA 25.1			

subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 2		
Cardiac disorders atrioventricular block first degree alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0		
Nervous system disorders dizziness alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  headache alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1  3 / 29 (10.34%) 3		
General disorders and administration site conditions chills alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  fatigue alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1  4 / 29 (13.79%) 4		
Gastrointestinal disorders abdominal pain alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  abdominal discomfort alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  abdominal distension	0 / 29 (0.00%) 0  1 / 29 (3.45%) 1		

alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 29 (0.00%)		
occurrences (all)	0		
abdominal pain upper			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 29 (0.00%)		
occurrences (all)	0		
dyspepsia			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	1 / 29 (3.45%)		
occurrences (all)	1		
diarrhoea			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	1 / 29 (3.45%)		
occurrences (all)	1		
constipation			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	8 / 29 (27.59%)		
occurrences (all)	8		
gastrooesophageal reflux disease			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	3 / 29 (10.34%)		
occurrences (all)	3		
flatulence			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	0 / 29 (0.00%)		
occurrences (all)	0		
eructation			
alternative dictionary used: MedDRA 25.1			
subjects affected / exposed	5 / 29 (17.24%)		
occurrences (all)	5		
vomiting			
alternative dictionary used: MedDRA 25.1			

<p>subjects affected / exposed</p> <p>8 / 29 (27.59%)</p> <p>occurrences (all)</p> <p>11</p> <p>nausea</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>12 / 29 (41.38%)</p> <p>occurrences (all)</p> <p>18</p>			
<p>Reproductive system and breast disorders</p> <p>balanoposthitis</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed<sup>[1]</sup></p> <p>1 / 11 (9.09%)</p> <p>occurrences (all)</p> <p>1</p> <p>erectile dysfunction</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed<sup>[2]</sup></p> <p>0 / 11 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>postmenopausal haemorrhage</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed<sup>[3]</sup></p> <p>0 / 18 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>vulvovaginal pruritus</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed<sup>[4]</sup></p> <p>1 / 18 (5.56%)</p> <p>occurrences (all)</p> <p>1</p>			
<p>Respiratory, thoracic and mediastinal disorders</p> <p>oropharyngeal pain</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>0 / 29 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Skin and subcutaneous tissue disorders</p> <p>alopecia</p> <p>alternative dictionary used: MedDRA 25.1</p> <p>subjects affected / exposed</p> <p>0 / 29 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
Renal and urinary disorders			



dysuria alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 3		
Musculoskeletal and connective tissue disorders back pain alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  arthralgia alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  myalgia alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  muscle spasms alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  pain in extremity alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 1  1 / 29 (3.45%) 1  3 / 29 (10.34%) 3  1 / 29 (3.45%) 1  1 / 29 (3.45%) 1		
Infections and infestations covid-19 alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  nasopharyngitis alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)  urinary tract infection	4 / 29 (13.79%) 4  0 / 29 (0.00%) 0		

alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0		
upper respiratory tract infection alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	2 / 29 (6.90%) 3		
sinusitis alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	1 / 29 (3.45%) 2		
Metabolism and nutrition disorders decreased appetite alternative dictionary used: MedDRA 25.1 subjects affected / exposed occurrences (all)	0 / 29 (0.00%) 0		

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
27 September 2021	Modified schedule of activities; - Objectives, overview of study periods and exclusion criteria were updated; - Provided additional guidance on Concomitant therapy; - Clarified QTc stopping criteria; - Changed wording regarding restarting study drug through IWRS; - Removed ABPM measurements and lipids measurements from exploratory efficacy assessments; - Statistical analysis general considerations were modified.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported